RxDoctor Payments Data

Toran Macarthur, MD

Family Medicine · Lehi, UTNPI 1063521177

Payments from drug & device makers

$10,114in general payments, 2019–2025

Across 628 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Astellas Pharma US Inc$808
  • AstraZeneca$779
  • Lilly USA, LLC$502
  • Pfizer$404
  • Boehringer Ingelheim$305
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$9,76297%
  • Education$3523%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)122$1,892
Astellas Pharma US Inc32$808
AstraZeneca50$779
Lilly USA, LLC32$502
Pfizer42$404
Boehringer Ingelheim16$305
Amgen19$302
Tris Pharma Inc16$288
Sanofi-aventis U.S. LLC20$275
Novo Nordisk17$261
Johnson & Johnson13$257
Supernus Pharmaceuticals, Inc.14$237
Ironshore Pharmaceuticals Inc.12$228
Antares Pharma, Inc.14$198
GSK14$188
Corium, LLC10$183
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$169
Axsome Therapeutics, Inc.8$164
Mylan Specialty L.p.7$160
Corcept Therapeutics7$160
Takeda Pharmaceuticals U.S.A., Inc.15$152
Boston Scientific7$113
Sunovion Pharmaceuticals Inc.8$111
Bayer6$98
Abbott4$85
Kowa Pharmaceuticals America, Inc.6$83
Daiichi Sankyo Inc.4$82
Phathom Pharmaceuticals, Inc.6$81
Avanir Pharmaceuticals, Inc.5$78
Amarin Pharma, Inc.5$78
Xeris Pharmaceuticals, Inc.4$75
Strongbridge US Inc.4$72
Mannkind Corporation4$70
Idorsia Pharmaceuticals US Inc4$68
Teva Pharmaceuticals USA, Inc.4$67
Cranial Technologies, Inc4$61
Merck4$60
Edwards Lifesciences3$57
Vanda Pharmaceuticals Inc.2$56
Nestle Healthcare Nutrition Inc.3$52
Novartis3$50
Aimmune Therapeutics, Inc.3$49
Otsuka America Pharmaceutical, Inc.3$47
Dexcom, Inc.2$46
Sumitomo Pharma America, Inc.4$38
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$38
Collegium Pharmaceutical, Inc.2$34
Jazz Pharmaceuticals Inc.2$31
Alnylam Pharmaceuticals Inc.2$30
Almatica Pharma LLC2$30
Biohaven Pharmaceuticals, Inc.2$29
Dynavax Technologies Corporation2$27
Alfasigma USA, Inc.2$27
Adlon Therapeutics L.p.2$26
Lundbeck LLC1$23
Ascendis Pharma Endocrinology Inc1$22
Viatris Specialty LLC1$22
Biohaven Pharmaceutical Holding Company Ltd.1$20
Medtronic1$20
Ultragenyx Pharmaceutical Inc.1$15

How this compares

$10,114 in reported general payments places this provider in the 90th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$124,353
Medicare patients
206
Services billed
7,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide77$90,699
JardianceEmpagliflozin67$70,894
OzempicSemaglutide48$54,450
TrulicityDulaglutide45$47,073
MyrbetriqMirabegron58$40,996
XareltoRivaroxaban43$40,511
FarxigaDapagliflozin Propanediol60$37,796
EliquisApixaban46$37,570
Tresiba Flextouch U-200Insulin Degludec21$21,395
JanuviaSitagliptin Phosphate23$19,494
TradjentaLinagliptin15$13,139
Tresiba Flextouch U-100Insulin Degludec25$9,146
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$8,333
Levothyroxine Sodium485$7,321
Breo ElliptaFluticasone/Vilanterol13$7,144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$502$137,772122 claims
Boehringer IngelheimJardiance, Tradjenta$305$84,03382 claims
Novo NordiskOzempic$261$54,45048 claims
AstraZenecaFarxiga, Symbicort$779$42,90278 claims
Astellas Pharma US IncMyrbetriq$808$40,99658 claims
Johnson & JohnsonXarelto$257$40,51143 claims
PfizerEliquis$404$37,57046 claims
MerckJanuvia$60$19,49423 claims
GSKBreo Ellipta$188$7,14413 claims
Sanofi-aventis U.S. LLCLantus$275$2,30412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 928 family medicine providers in Utah.

Other family medicine in Lehi

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →